EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial

Weiqing Wang, Stephen C Bain, Fang Bian, Rui Chen, Sanaz Gabery, Shan Huang, Thomas B Jensen, Bifen Luo, Guoyue Yuan, Guang Ning, PIONEER 11 investigators

Diabetologia · 2024-09 · 67 (9) · 1783-1799

DOI: 10.1007/s00125-024-06142-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetologia, online erschienen am 10.07.2024. Verfasst von Weiqing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/hypothesis The aim of this study was to evaluate the efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes insufficiently controlled with diet and exercise alone.

Methods

The Peptide Innovation for Early Diabetes Treatment (PIONEER) 11 trial was a double-blind, randomised, Phase IIIa trial conducted across 52 sites in the China region (mainland China and Taiwan), Hungary, Serbia and Ukraine. Eligible participants were ≥18 years (≥20 years in Taiwan), had a diagnosis of type 2 diabetes with HbA 1c 53–86 mmol/mol (7.0–10.0%) and were not receiving any glucose-lowering drugs. After a 4-week run-in period in which participants were treated with diet and exercise alone, those who fulfilled the randomisation criteria were randomised (1:1:1:1) using a web-based randomisation system to receive once-daily oral semaglutide 3 mg, 7 mg or 14 mg or placebo for 26 weeks (using a 4-week dose-escalation regimen for the higher doses). Randomisation was stratified according to whether participants were from the China region or elsewhere. The primary and confirmatory secondary endpoints were change from baseline to week 26 in HbA 1c and body weight (kg), respectively. Safety was assessed in all participants exposed to at least one dose of the trial product.

Results

Between October 2019 and October 2021, a total of 774 participants were screened and 521 participants were randomised to oral semaglutide 3 mg ( n =130), 7 mg ( n =130), 14 mg ( n =130) or placebo ( n =131); most participants (92.5%, n =482) completed the trial, with 39 participants prematurely discontinuing treatment. The number of participants contributing to the trial analyses was based on the total number of participants who were randomised at the beginning of the trial. The majority of participants were male (63.7%), and the mean age of participants was 52 years. At baseline, mean HbA 1c and body weight were 63 mmol/mol (8.0%) and 79.6 kg, respectively. Oral semaglutide resulted in significantly greater reductions in HbA 1c than placebo at week 26 ( p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralBlood GlucoseChinaDouble-Blind MethodEast Asian PeopleGlucagon-Like PeptidesGlycated HemoglobinTreatment OutcomeSemaglutide

Stichwörter der Autor:innen

ChinaGLP-1 analogueGlycaemic controlIncretin therapyPhase IIISemaglutideType 2 diabetes

Substanzen

Blood GlucoseGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Diabetes Research Unit, University of Swansea, Swansea, UK. bainsc60@mail.com.
  • Department of Endocrinology, Cangzhou People's Hospital, Cangzhou, China.
  • Novo Nordisk (China) Pharmaceuticals Co. Ltd., Beijing, China.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Endocrinology Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Wang, W., Bain, S. C., Bian, F., Chen, R., Gabery, S., Huang, S., Jensen, T. B., Luo, B., Yuan, G., Ning, G., & PIONEER 11 investigators (2024). Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Diabetologia, 67(9), 1783-1799. https://doi.org/10.1007/s00125-024-06142-3

Vancouver

Wang W, Bain SC, Bian F, Chen R, Gabery S, Huang S, et al. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Diabetologia. 2024;67(9):1783-1799. doi:10.1007/s00125-024-06142-3

BibTeX
@article{Wang2024,
  author = {Wang, Weiqing and Bain, Stephen C and Bian, Fang and Chen, Rui and Gabery, Sanaz and Huang, Shan and Jensen, Thomas B and Luo, Bifen and Yuan, Guoyue and Ning, Guang and PIONEER 11 investigators, PIONEER 11 investigators},
  title = {Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial},
  journal = {Diabetologia},
  year = {2024},
  volume = {67},
  number = {9},
  pages = {1783--1799},
  doi = {10.1007/s00125-024-06142-3}
}
Kostenlos starten →